iBio (NYSEA:IBIO) will present two posters about its intelligence-powered RubrYc discovery engine at the Antibody Engineering and Therapeutics Conference in San Diego on Dec. 4-8.
The conference features the latest science and research in antibody engineering, design, and selection to drive commercial advances in fields such as immuno-oncology.
iBio will highlight applications of its RubrYc discovery engine in two posters, including:
- “Epitope-Targeted Antibody Discovery with AI-Designed Structural Immunogens,” including applications for two challenging targets, a PD-1 agonist and the EGFRvIII tumor-specific epitope, presented by Alexander Taguchi, Ph.D., director of machine learning.
- “Fully Human and Developable Antibody Optimization Libraries Using Human Sequence-Trained AI and Mammalian Display,” demonstrating the identification of a more potent PD-1 agonist antibody, a CCR8 ADCC cell- killing assay, and use of the EGFRvIII tumor-specific epitope to target and kill tumor cells while preserving healthy cells, presented by Matthew Greving, Ph.D., VP of platform technology and machine learning.
The RubrYc discovery engine is designed to tackle complex and challenging drug targets with the goal of developing safer and more effective immunotherapies for difficult-to-treat cancers. By combining proprietary epitope steering with an advanced library, the RubrYc discovery engine consistently delivers hits on difficult targets in a fraction of the time of traditional lead optimization.
